Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $18.58, but opened at $20.14. Pacira BioSciences shares last traded at $20.63, with a volume of 72,556 shares traded.
Analyst Ratings Changes
Several brokerages have recently weighed in on PCRX. HC Wainwright restated a "buy" rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada upped their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Barclays dropped their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and an average price target of $23.50.
Check Out Our Latest Stock Report on PCRX
Pacira BioSciences Price Performance
The company has a market capitalization of $953.01 million, a P/E ratio of -10.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company has a fifty day moving average price of $18.27 and a 200 day moving average price of $17.74.
Hedge Funds Weigh In On Pacira BioSciences
Hedge funds and other institutional investors have recently modified their holdings of the company. Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences in the 3rd quarter valued at approximately $98,000. State Street Corp increased its holdings in shares of Pacira BioSciences by 5.8% during the third quarter. State Street Corp now owns 2,014,012 shares of the company's stock valued at $30,311,000 after purchasing an additional 110,162 shares during the period. Centiva Capital LP bought a new stake in shares of Pacira BioSciences during the third quarter valued at about $398,000. PDT Partners LLC acquired a new stake in Pacira BioSciences in the third quarter worth about $3,469,000. Finally, Verition Fund Management LLC bought a new position in Pacira BioSciences in the 3rd quarter valued at about $493,000. Institutional investors and hedge funds own 99.73% of the company's stock.
Pacira BioSciences Company Profile
(
Get Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Recommended Stories
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
